A Prospective, DB, Randomized, Placebo-controlled Clinical Trial of IC Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2018
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms AMICI
- Sponsors Angioblast Systems; Mesoblast
- 07 Jun 2018 This trail has been completed in Netherlands.
- 07 Apr 2018 This trial has been completed in Denmark.
- 18 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2018.